Details for Patent: 5,380,709
✉ Email this page to a colleague
Title: | Prostaglandins E and anti ulcers containing same |
Abstract: | The novel 13, 14-dihydro-15-keto prostaglandins E of the invention have remarkable preventive effects against ulcers. Further, the novel 13,14-dihydro-15-keto prostaglandins E of the invention have an advatage that they have none of side effects which prostaglandin E intrinsically has, or can remarakably reduce such effects of the prostaglandin E. Therefore, the novel 13, 14-dihydro-15-keto prostaglandins E of the invention are effective for animal and human use for treatment and prevention of ulcers, such as duodenal ulcer and gastric ulcer. |
Inventor(s): | Ueno; Ryuzo (Nishinomiya, JP), Ueno; Ryuji (Kyoto, JP), Kato; Ichie (Kawanishi, JP), Oda; Tomio (Itami, JP) |
Assignee: | K.K. Ueno Seiyaku Oyo Kenkyujo (Osaka, JP) |
Filing Date: | Apr 28, 1993 |
Application Number: | 08/053,561 |
Claims: | 1. Prostaglandins E represented by a general formula: in which X represents: ##STR47## R.sub.1 represents: a hydrogen atom, a physiologically acceptable salt residue, or an ester residue selected from the group consisting of alkyl, benzyl, hydroxyalkyl, alkoxyalkyl, alkylsilyl and tetrahydropyranyl group; R.sub.2 represents: a hydrogen atom or a methyl group; R.sub.3 represents: a hydroxyl or hydroxymethyl group; R.sub.4 represents: a hydrogen atom; R.sub.5 represents: a hydrogen atom; R.sub.6 represents: a C.sub.5 -C.sub.9 alkyl group which may have a branch or a double bond, in which the C.sub.2 -C.sub.3 bond is a single bond. 2. Prostaglandin E as described in claim 1, wherein X is ##STR48## 3. Prostaglandin E as described in claim 1, wherein X is ##STR49## 4. Prostaglandin E as described in claim 1, wherein R.sub.6 is C.sub.6 -C.sub.9 alkyl group. 5. Prostaglandin E as described in claim 1, wherein the general formula is ##STR50## 6. Prostaglandin E as described in claim 5, being 13,14-dihydro-6,15-diketo-19-methyl-PGE.sub.1 or alkyl ester thereof. 7. An anti-ulcer composition comprising an anti-ulcer effective amount of a prostaglandin E represented by a general formula: ##STR51## in which X represents: ##STR52## R.sub.1 represents: a hydrogen atom, a physiologically acceptable salt residue, or an ester residue selected from the group consisting of alkyl, benzyl, hydroxyalkyl, alkoxyalkyl, alkylsilyl and tetrahydropyranyl group; R.sub.2 represents: a hydrogen atom or a methyl group; R.sub.3 represents: a hydroxyl or hydroxymethyl group; R.sub.4 represents: a hydrogen atom; R.sub.5 represents: a hydrogen atom; R.sub.6 represents: a C.sub.5 -C.sub.9 alkyl group which may have a branch or a double bond, in which the C.sub.2 -C.sub.3 bond is a single bond. 8. An anti-ulcer composition as described in claim 7, wherein X is ##STR53## 9. An anti-ulcer composition as described in claim 7, wherein X is ##STR54## 10. An anti-ulcer composition as described in claim 7, wherein R.sub.6 is C.sub.6 -C.sub.9 alkyl group. 11. An anti-ulcer composition as described in claim 7, wherein the general formula is ##STR55## 12. An anti-ulcer composition as described in claim 11, being 13,14-dihydro-6,15-diketo-19-methyl-PGE.sub.1 or alkyl ester thereof. |